Ten years ago, Victoria Hale wrote a manifesto targeting five diseases in need of drug development and turned it into a business plan for the first pharmaceutical not-for-profit in the United States. Today, her organization, the Institute for OneWorld Health, is on the verge of proving that its no-profit/no-loss model can work. Its first drug, paromomycin -- a treatment for visceral leishmaniasis, an illness spread by sand flies that mostly afflicts the poorest of the poor -- is months from completing its final stage of clinical trials. Up next: malaria. Backed by a $42.6 million grant from the Gates Foundation, OneWorld Health aims to create and market semisynthetic artemisinin, a key malaria-fighting ingredient that's in short supply.
Email
Digg
StumbleUpon
Facebook
Buzz Up!
LinkedIn
Recent Comments | 2 Total
September 20, 2009 at 2:47pm by john smith
great article. its Great to see woman doing something great
Honda Accessories
November 17, 2009 at 8:44pm by Arthur Chachuna
What a worthy course. I really hope you guys will succeed!
--
Arthur,
best bank rates | work positions